Dr.B.Ranjith Karthekeyan

Liposomal drug delivery methods are becoming popular nanocarriers for anticancer drugs because they make the drugs more available, target them more accurately, and lower their toxicity in the body. The goal of this project was to improve cancer treatment results by designing, formulating, and testing liposomal systems that include a model chemotherapeutic drug. We used the thin-film hydration approach to make three liposomal formulations (F1, F2, and F3) and then measured their particle size, zeta potential, polydispersity index, and entrapment efficiency. Studies of drug release in vitro showed that the drugs were released over time, with F3 exhibiting the largest cumulative release (89% at 24 hours). The MTT assay showed that F3 dramatically reduced the viability of MCF-7 cells (to 12% at 50 µg/mL), making it better than both other formulations and the free medication. One-way ANOVA statistical analysis showed that there were substantial differences (p